These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

421 related articles for article (PubMed ID: 34547581)

  • 1. Trifluridine/tipiracil in combination with oxaliplatin and either bevacizumab or nivolumab in metastatic colorectal cancer: a dose-expansion, phase I study.
    Bordonaro R; Calvo A; Auriemma A; Hollebecque A; Rubovszky G; Saunders MP; Pápai Z; Prager G; Stein A; André T; Argilés G; Cubillo A; Dahan L; Edeline J; Leger C; Cattan V; Fougeray R; Amellal N; Tabernero J
    ESMO Open; 2021 Oct; 6(5):100270. PubMed ID: 34547581
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase I dose-escalation of trifluridine/tipiracil in combination with oxaliplatin in patients with metastatic colorectal cancer.
    Argilés G; André T; Hollebecque A; Calvo A; Dahan L; Cervantes A; Leger C; Amellal N; Fougeray R; Tabernero J
    Eur J Cancer; 2019 May; 112():12-19. PubMed ID: 30889492
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase II study of trifluridine/tipiracil plus bevacizumab by RAS mutation status in patients with metastatic colorectal cancer refractory to standard therapies: JFMC51-1702-C7.
    Takahashi T; Yamazaki K; Oki E; Shiozawa M; Mitsugi K; Makiyama A; Nakamura M; Ojima H; Kagawa Y; Matsuhashi N; Okuda H; Asayama M; Yuasa Y; Shimada Y; Manaka D; Watanabe J; Oba K; Yoshino T; Yoshida K; Maehara Y
    ESMO Open; 2021 Apr; 6(2):100093. PubMed ID: 33744811
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Trifluridine/Tipiracil Plus Bevacizumab for Vulnerable Patients With Pretreated Metastatic Colorectal Cancer: A Retrospective Study (WJOG14520G).
    Kito Y; Kawakami H; Mitani S; Nishina S; Matsumoto T; Tsuzuki T; Shinohara Y; Shimokawa H; Kumanishi R; Ohta T; Katsuya H; Kawakami T; Nishina T; Hasegawa H; Akiyoshi K; Chiba Y; Yamazaki K; Hironaka S; Muro K
    Oncologist; 2024 Mar; 29(3):e330-e336. PubMed ID: 37950903
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A phase 2 trial of trifluridine/tipiracil plus nivolumab in patients with heavily pretreated microsatellite-stable metastatic colorectal cancer.
    Patel MR; Falchook GS; Hamada K; Makris L; Bendell JC
    Cancer Med; 2021 Feb; 10(4):1183-1190. PubMed ID: 33544407
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A phase I study to determine the maximum tolerated dose of trifluridine/tipiracil and oxaliplatin in patients with refractory metastatic colorectal cancer: LUPIN study.
    Suenaga M; Wakatsuki T; Mashima T; Ogura M; Ichimura T; Shinozaki E; Nakayama I; Osumi H; Ota Y; Takahari D; Chin K; Seimiya H; Yamaguchi K
    Invest New Drugs; 2020 Feb; 38(1):111-119. PubMed ID: 30838483
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and Safety of Trifluridine/Tipiracil-Containing Combinations in Colorectal Cancer and Other Advanced Solid Tumors: A Systematic Review.
    Shitara K; Falcone A; Fakih MG; George B; Sundar R; Ranjan S; Van Cutsem E
    Oncologist; 2024 May; 29(5):e601-e615. PubMed ID: 38366864
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Trifluridine/tipiracil plus bevacizumab as a first-line treatment for elderly patients with metastatic colorectal cancer (KSCC1602): A multicenter phase II trial.
    Oki E; Makiyama A; Miyamoto Y; Kotaka M; Kawanaka H; Miwa K; Kabashima A; Noguchi T; Yuge K; Kashiwada T; Ando K; Shimokawa M; Saeki H; Akagi Y; Baba H; Maehara Y; Mori M
    Cancer Med; 2021 Jan; 10(2):454-461. PubMed ID: 33249761
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Trifluridine/tipiracil + oxaliplatin ± nivolumab vs FOLFOX ± nivolumab in HER2 negative advanced oesogastric adenocarcinoma: The PRODIGE73-UCGI40-LOGICAN trial.
    Botsen D; Chabaud S; Perrier H; Ammarguellat H; Jestin-Le-Tallec V; Olesinski J; Toullec C; Aparicio T; Ben Abdelghani M; Borg C; Bouche O; Coutzac C; Devaud H; Di Fiore F; Dubreuil O; Evesque L; Huguenin B; Muller M; Poureau PG; Oularue E; Tougeron D; Zaanan A; Ammari S; De Sousa Carvalho N; Decazes P; De La Fouchardiere C
    Dig Liver Dis; 2024 Aug; 56(8):1281-1287. PubMed ID: 38762353
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Trifluridine/Tipiracil plus Oxaliplatin Improves PD-1 Blockade in Colorectal Cancer by Inducing Immunogenic Cell Death and Depleting Macrophages.
    Limagne E; Thibaudin M; Nuttin L; Spill A; Derangère V; Fumet JD; Amellal N; Peranzoni E; Cattan V; Ghiringhelli F
    Cancer Immunol Res; 2019 Dec; 7(12):1958-1969. PubMed ID: 31611243
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase I Study of Trifluridine/Tipiracil Plus Irinotecan and Bevacizumab in Advanced Gastrointestinal Tumors.
    Varghese AM; Cardin DB; Hersch J; Benson AB; Hochster HS; Makris L; Hamada K; Berlin JD; Saltz LB
    Clin Cancer Res; 2020 Apr; 26(7):1555-1562. PubMed ID: 31924737
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Study protocol of the FIRE-8 (AIO-KRK/YMO-0519) trial: a prospective, randomized, open-label, multicenter phase II trial investigating the efficacy of trifluridine/tipiracil plus panitumumab versus trifluridine/tipiracil plus bevacizumab as first-line treatment in patients with metastatic colorectal cancer.
    Sommerhäuser G; Kurreck A; Stintzing S; Heinemann V; von Weikersthal LF; Dechow T; Kaiser F; Karthaus M; Schwaner I; Fuchs M; König A; Roderburg C; Hoyer I; Quante M; Kiani A; Fruehauf S; Müller L; Reinacher-Schick A; Ettrich TJ; Stahler A; Modest DP
    BMC Cancer; 2022 Jul; 22(1):820. PubMed ID: 35897060
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impact of KRAS
    Tabernero J; Taieb J; Fakih M; Prager GW; Van Cutsem E; Ciardiello F; Mayer RJ; Amellal N; Skanji D; Calleja E; Yoshino T
    ESMO Open; 2024 Mar; 9(3):102945. PubMed ID: 38471240
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Trifluridine-Tipiracil and Bevacizumab in Refractory Metastatic Colorectal Cancer.
    Prager GW; Taieb J; Fakih M; Ciardiello F; Van Cutsem E; Elez E; Cruz FM; Wyrwicz L; Stroyakovskiy D; Pápai Z; Poureau PG; Liposits G; Cremolini C; Bondarenko I; Modest DP; Benhadji KA; Amellal N; Leger C; Vidot L; Tabernero J;
    N Engl J Med; 2023 May; 388(18):1657-1667. PubMed ID: 37133585
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase I study of trifluridine/tipiracil (TAS-102) plus irinotecan in combination with bevacizumab as a second-line therapy for patients with metastatic colorectal cancer.
    Zhang J; Yang W; Liu J; Wang N; Ren Z; Yang T; Xie G; Wu G; Sun Y
    Invest New Drugs; 2024 Aug; 42(4):454-461. PubMed ID: 38990451
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Neutropenia is an indicator of outcomes in metastatic colorectal cancer patients treated with FTD/TPI plus bevacizumab: a retrospective study.
    Nose Y; Kagawa Y; Hata T; Mori R; Kawai K; Naito A; Sakamoto T; Murakami K; Katsura Y; Ohmura Y; Masuzawa T; Takeno A; Takeda Y; Kato T; Murata K
    Cancer Chemother Pharmacol; 2020 Sep; 86(3):427-433. PubMed ID: 32816155
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pooled safety analysis from phase III studies of trifluridine/tipiracil in patients with metastatic gastric or gastroesophageal junction cancer and metastatic colorectal cancer.
    Van Cutsem E; Hochster H; Shitara K; Mayer R; Ohtsu A; Falcone A; Yoshino T; Doi T; Ilson DH; Arkenau HT; George B; Benhadji KA; Makris L; Tabernero J
    ESMO Open; 2022 Dec; 7(6):100633. PubMed ID: 36455504
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Retrospective cohort study of trifluridine/tipiracil (TAS-102) plus bevacizumab versus trifluridine/tipiracil monotherapy for metastatic colorectal cancer.
    Kotani D; Kuboki Y; Horasawa S; Kaneko A; Nakamura Y; Kawazoe A; Bando H; Taniguchi H; Shitara K; Kojima T; Tsuji A; Yoshino T
    BMC Cancer; 2019 Dec; 19(1):1253. PubMed ID: 31881856
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A Phase II Study of FOLFIRI Plus Ziv-Aflibercept After Trifluridine/Tipiracil Plus Bevacizumab in Patients with Metastatic Colorectal Cancer: WJOG 11018G.
    Matsumoto T; Yamamoto Y; Kotaka M; Masuishi T; Tsuji Y; Shoji H; Hirata K; Tsuduki T; Makiyama A; Izawa N; Takahashi N; Tsuda M; Yasui H; Ohta T; Kito Y; Otsu S; Hironaka S; Yamazaki K; Boku N; Hyodo I; Yoshimura K; Muro K
    Target Oncol; 2024 Mar; 19(2):181-190. PubMed ID: 38427280
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A Phase I dose-escalation study of third-line regorafenib with trifluridine/tipiracil in metastatic colorectal cancer.
    Moehler M; Michel M; Stein A; Trojan J; Marquardt J; Tintelnot J; Waidmann O; Weinmann A; Woerns MA; Schroeder H; Maenz M; Foerster F
    Future Oncol; 2021 Sep; 17(25):3309-3319. PubMed ID: 33993741
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.